2012-11-12T17:38:11-06:00 2011-12-31 861065772 DELOITTE TAX LLP 655 WEST BROADWAY SUITE 700 SAN DIEGO CA 921018590 990 2011-01-01 330328688 LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY LAJO 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 92037 301510 8587526500 2012-11-12 1 DIANA J MCCUTCHEN P00545657 6192326500 2011 2016-02-24 21:20:13Z CHARLES CARPOWICH 9420 ATHENA CIRCLE LA JOLLA CA 92037 48476358 0 X WWW.LIAI.ORG X 1988 CA BIOMEDICAL RESEARCH MAKING BREAKTHROUGH DISCOVERIES LEADING TO NEW TREATMENTS AND CURES. 13 11 386 53 164527 59769 38763253 43377978 4264931 3608126 102355 103116 501829 1345748 43632368 48434968 2500 0 0 0 24616497 24872839 0 0 242577 21197504 21441400 45816501 46314239 -2184133 2120729 30922104 27262976 14845708 9065851 16076396 18197125 X AT THE LA JOLLA INSTITUTE, OUR PURPOSE IS MAKING DISCOVERIES TOWARD NEW TREATMENTS OR CURES TO END THE SUFFERING WROUGHT BY THE HOST OF DISEASES RELATED TO IMMUNE SYSTEM FUNCTION. THESE RANGE FROM DIABETES TO HEART DISEASE TO INFECTIOUS DISEASES TO CANCER. 0 0 40775677 3608126 LA JOLLA INSTITUTE IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE RANKING AMONG THE TOP FIVE ORGANIZATIONS IN THE WORLD FOR RESEARCH IMPACT IN IMMUNOLOGY. SPECIFICALLY, OUR SCIENTISTS CARRY OUT RESEARCH FOCUSED ON THE PREVENTION OF DISEASE THROUGH THE DEVELOPMENT OF VACCINES AND THE TREATMENT AND CURE OF NUMEROUS DISEASES RELATED TO IMMUNE SYSTEM FUNCTION AND INFLAMMATION. IMMUNE SYSTEM DISORDERS AFFECT MILLIONS AND INCLUDE MANY OF SOCIETY'S MOST DEBILITATING ILLNESSES. OUR RESEARCH FOCUSES ON FIVE MAJOR AREAS: 1. AUTOIMMUNE DISEASES SUCH AS TYPE 1 DIABETES AND RHEUMATOID ARTHRITIS 2. CANCER AND STIMULATING ANTI-TUMOR RESPONSES 3. INFECTIOUS DISEASES SUCH AS TUBERCULOSIS, FLU AND DENGUE VIRUS 4. ALLERGY AND ASTHMA AND CONTROLLING HARMFUL IMMUNE REACTIONS 5. VASCULAR IMMUNOLOGY INCLUDING HEART DISEASE AND TYPE 2 DIABETES. RANKED AS ONE OF THE TOP ORGANIZATIONS IN THE WORLD FOR RESEARCH IMPACT IN IMMUNOLOGY, THE LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY BRINGS TO BEAR A COMPREHENSIVE RESEARCH EFFORT TO UNDERSTAND THE DIVERSE ASPECTS OF IMMUNE-MEDIATED DISEASES AND TO ADVANCE PROGRESS TOWARD THEIR PREVENTION, TREATMENT AND CURE. IMMUNE SYSTEM DISORDERS AFFECT MILLIONS AND INCLUDE MANY OF SOCIETY'S MOST DEBILITATING ILLNESSES. THESE RANGE FROM CHRONIC, SEVERE AUTOIMMUNE DISORDERS SUCH AS RHEUMATOID ARTHRITIS, TYPE 1 DIABETES, MULTIPLE SCLEROSIS AND CROHN'S DISEASE TO IMMUNE SYSTEM MALFUNCTIONS UNDERLYING HEART DISEASE AND CANCER, THE NATION'S NO. 1 AND NO. 2 KILLERS RESPECTIVELY. ITS RESEARCHERS ALSO EXPLORE HOW THE IMMUNE SYSTEM RESPONDS TO INFECTIOUS DISEASES AND IS USING THIS KNOWLEDGE TO ADVANCE THE DEVELOPMENT OF NEW VACCINES. A NONPROFIT, THE INSTITUTE WAS FOUNDED IN 1988 AND IS HOME TO 22 INDEPENDENT LABORATORIES, EACH OPERATED BY A LEADING SCIENTIST WHO OVERSEES EFFORTS TO UNLOCK THE MYSTERIES OF IMMUNE SYSTEM FUNCTIONING. SUPPORTING THESE EFFORTS ARE THE INSTITUTE'S MORE THAN 300 EMPLOYEES - ABOUT HALF OF WHOM HOLD DOCTORAL DEGREES (PH.D. OR M.D.) FROM NUMEROUS COUNTRIES AROUND THE WORLD. ALTHOUGH RELATIVELY YOUNG, THE INSTITUTE HAS ACCOMPLISHED MUCH IN ITS SHORT HISTORY, AND WAS RECENTLY RANKED AMONG THE TOP FIVE ORGANIZATIONS FOR RESEARCH IMPACT IN IMMUNOLOGY WORLDWIDE (AS MEASURED BY CITATIONS PER PUBLICATION) BY THE RATING AGENCY THOMSON REUTERS. IN ADDITION, THREE OF ITS SCIENTISTS ARE AMONG THE MOST HIGHLY CITED IMMUNOLOGISTS IN THE WORLD -- A DISTINCTION HELD BY LESS THAN ONE HALF OF ONE PERCENT OF ALL PUBLISHING SCIENTIFIC AUTHORS. SEVERAL OF ITS FACULTY MEMBERS ALSO SERVE ON NATIONAL INSTITUTES OF HEALTH (NIH) GRANT REVIEW PANELS, WHICH ARE APPOINTMENTS THAT SIGNAL A HIGH DEGREE OF RESPECT FROM PEERS. ITS SCIENTISTS ALSO REGULARLY PUBLISH RESEARCH PAPERS DESCRIBING THEIR LATEST FINDINGS, MANY OF THESE APPEARING IN THE WORLD'S MOST PRESTIGIOUS SCIENTIFIC JOURNALS.THE INSTITUTE RECEIVES THE MAJORITY OF ITS FUNDING THROUGH COMPETITIVE RESEARCH GRANTS FROM THE NIH AND IS GROWING ITS PHILANTHROPIC OPPORTUNITIES TO FULFILL PRIORITY NEEDS. THIS INCLUDES FUNDING FOR NEW AREAS OF RESEARCH, CUTTING-EDGE TECHNOLOGIES AND CONTINUING RECRUITMENT OF THE VERY BEST SCIENTISTS.IT IS GUIDED BY A BOARD OF DIRECTORS COMPOSED OF RESPECTED BUSINESS EXECUTIVES, SCIENTISTS AND OTHER COMMUNITY LEADERS WHO DONATE THEIR TIME TO OVERSEE THE INSTITUTE'S ACTIVITIES. A SCIENTIFIC ADVISORY BOARD OF DISTINGUISHED OUTSIDE SPECIALISTS CONDUCTS ANNUAL EVALUATIONS OF SCIENTIFIC PROGRESS AND REVIEWS FUTURE RESEARCH OBJECTIVES.LA JOLLA INSTITUTE RESEARCHERS CONTINUED TO MAKE IMPRESSIVE RESEARCH ADVANCEMENTS IN 2011, WITH 138 RESEARCH PAPERS PUBLISHED IN SCIENTIFIC JOURNALS, INCLUDING 35 PAPERS (NEARLY 25 PERCENT) THAT WERE PUBLISHED IN HIGH-IMPACT JOURNALS. THIS INCLUDED SEVEN PAPERS IN THE NATURE PUBLISHING GROUP OF JOURNALS, WHICH ARE CONSIDERED AMONG THE MOST PRESTIGIOUS SCIENTIFIC JOURNALS IN THE WORLD. THE INSTITUTE'S MAJOR PUBLISHED FINDINGS IN 2011 ILLUSTRATE THE RANGE AND POWER OF IMMUNOLOGY RESEARCH AND ITS IMPACT ON A BROAD GROUP OF HUMAN HEALTH ISSUES. THIS INCLUDED DR. MATTHIAS VON HERRATH'S CREATION OF THE WORLD'S FIRST MOVIES SHOWING THE CELLULAR PROGRESSION OF TYPE 1 DIABETES IN REAL-TIME IN MOUSE MODELS, PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION. THE VIDEOS REPRESENTED AN EXTRAORDINARY TECHNICAL FEAT AND PROVIDED SURPRISING INFORMATION ABOUT THE SEARCH AND DESTROY MISSION OF T CELLS, WHICH KILL INSULIN-PRODUCING BETA CELLS IN THE PANCREAS, LEADING TO TYPE 1 DIABETES. THESE NEW INSIGHTS COULD PROFOUNDLY AFFECT FUTURE DIRECTIONS IN TYPE 1 DIABETES RESEARCH. AMONG THE INSTITUTE'S OTHER MAJOR FINDINGS IN 2011 WERE: DR. AMNON ALTMAN'S FINDING, PUBLISHED IN NATURE IMMUNOLOGY, IDENTIFYING A KEY MOLECULAR INTERACTION REQUIRED FOR T CELL ACTIVATION, WHICH COULD PROVIDE A THERAPEUTIC TARGET FOR TREATING AUTOIMMUNITY; DR. MICHAEL CROFT'S DISCOVERY OF A NEW WAY TO BLOCK AIRWAY REMODELING, PUBLISHED IN NATURE MEDICINE, WHICH COULD LEAD TO NEW THERAPIES FOR PEOPLE WITH SEVERE ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); DR. HILDE CHEROUTRE'S FINDING ON THE GENERATION OF IMMUNE MEMORY AT THE BODY'S MUCOSAL BORDERS, PUBLISHED IN NATURE IMMUNOLOGY, A MAJOR DISCOVERY WITH IMPLICATIONS FOR CREATING VACCINES AGAINST AIDS AND OTHER INFECTIONS, AND DR. TOSHIAKI KAWAKAMI'S DISCOVERY, PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, THAT IDENTIFIED TWO NOVEL THERAPEUTIC TARGETS FOR BLOCKING CELLULAR INTERACTIONS LONG KNOWN TO BE CENTRAL PLAYERS IN ALLERGIES. IN ADDITION, FIVE INSTITUTE DISCOVERIES, UNDERLYING A NUMBER OF POTENTIAL THERAPIES, ADVANCED IN THE PHARMACEUTICAL PIPELINE IN 2011, THREE OF THEM IN CLINICAL TRIALS. THESE INCLUDE A TRIAL ON A NEW THERAPY FOR INFLAMMATORY BOWEL DISEASE (CROHN'S AND COLITIS) AND ANOTHER TRIAL ON SICKLE CELL DISEASE, A DEVASTATING ILLNESS THAT AFFECTS 100,000 AMERICANS AND SEVERAL MILLION PEOPLE WORLDWIDE. AMONG THE OTHER MAJOR HIGHLIGHTS IN 2011, THE INSTITUTE: - JOINED A PRESTIGIOUS STEM CELL RESEARCH CONSORTIUM -- THE INSTITUTE BECAME THE FIFTH ORGANIZATION IN THE SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE IN 2011, JOINING COLLEAGUES FROM THE SALK INSTITUTE, THE SCRIPPS RESEARCH INSTITUTE, UC SAN DIEGO AND THE SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE IN THE FIRST-OF-ITS-KIND STEM CELL RESEARCH COLLABORATION. OPENED IN NOVEMBER, THE CONSORTIUM MARSHALS THE INTELLECTUAL RESOURCES OF THE FIVE ORGANIZATIONS-ALL WORLD-LEADERS IN LIFE SCIENCES-TOWARD IMPROVING HUMAN HEALTH THROUGH STEM CELL RESEARCH.- MAINTAINED LEADERSHIP OF AN INNOVATIVE WORLDWIDE RESEARCH TOOL - THE INSTITUTE RECEIVED A SEVEN-YEAR, $22 MILLION NIH CONTRACT RENEWAL TO CONTINUE ITS STEWARDSHIP OF THE IMMUNE EPITOPE DATABASE (IEDB). THE IEDB IS THE WORLD'S LARGEST COLLECTION OF SCIENTIFIC DATA ON HOW THE IMMUNE SYSTEM RESPONDS TO A WIDE RANGE OF DISEASES. IT CONTAINS THOUSANDS OF PIECES OF INFORMATION CRITICAL TO RESEARCHERS ATTEMPTING TO DESIGN NEW VACCINES OR TREATMENTS FOR AUTOIMMUNE DISORDERS.- OPENED RNA INTERFERENCE (RNAI) GENOMICS RESEARCH CENTER -- THE INSTITUTE OPENED A DEDICATED RNAI CENTER IN 2011, ONE OF THE FEW SUCH CENTERS IN THE WORLD. RNAI IS A NOBEL PRIZE-WINNING TECHNOLOGY THAT ENABLES RESEARCHERS TO TURN OFF INDIVIDUAL GENES TO DETERMINE HOW THEY FIT INTO DISEASE PROCESSES. THE INSTITUTE'S CENTER WAS FINANCED BY A $12.6 MILLION NIH GRANT AND FEATURES THE LATEST IN HIGH-SPEED RNAI SEQUENCING TECHNOLOGIES, WHICH ENABLE SCIENTISTS TO RAPIDLY SIFT THROUGH THOUSANDS OF GENES. - CELEBRATED ITS FIFTH ANNIVERSARY IN THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (UCSD) SCIENCE RESEARCH PARK - LEADERS FROM THE LA JOLLA INSTITUTE AND UCSD GATHERED ON JULY 1ST, 2011 TO CELEBRATE FIVE YEARS OF EXCITING GROWTH AND NEW COLLABORATIONS IN THE ONGOING BATTLE AGAINST DISEASE. WHILE MAINTAINING ITS INDEPENDENCE AS A SEPARATE PRIVATE ENTITY, THE INSTITUTE MOVED INTO A NEWLY CONSTRUCTED STATE-OF-THE ART RESEARCH FACILITY IN THE UNIVERSITY'S SCIENCE RESEARCH PARK IN 2006. THE NEW FACILITY ALLOWED FOR MORE SPACE AND ENHANCED SCIENTIFIC DESIGN ALONG WITH SPURRING MORE COLLABORATION AND JOINT PROJECTS BETWEEN RESEARCHERS FROM UCSD AND THE LA JOLLA INSTITUTE. IN ADDITION TO THEIR RESEARCH ACTIVITIES IN 2011, INSTITUTE SCIENTISTS ALSO LECTURED AT MEDICAL RESEARCH SEMINARS THROUGHOUT THE WORLD AND ORGANIZED NUMEROUS SCIENTIFIC CONFERENCES. WHILE IT IS DIFFICULT TO DETERMINE THE NUMBER OF PERSONS BENEFITED BECAUSE OF THE BROAD APPLICABILITY OF THE LA JOLLA INSTITUTE'S FINDINGS AND ACCOMPLISHMENTS, THE INSTITUTE ESTIMATES THAT THOUSANDS OF RESEARCH AND CLINICAL SCIENTISTS ATTENDED THE ABOVE MENTIONED CONFERENCES, READ THE INSTITUTE'S PUBLICATIONS, AND/OR DIRECTLY COLLABORATED WITH OUR SCIENTISTS, AND AS A RESULT, NOW INCORPORATE PORTIONS OF OUR RESEARCH INTO THEIR WORK. 40775677 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 1 1 0 0 0 0 1 0 0 0 0 0 1 126 0 1 386 1 1 1 0 0 0 0 0 0 0 0 0 0 X 13 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA CT NY OH VA IL MD NC FL MI WI AZ NJ PA WA GA RI UT MO TX MT X CHARLES CARPOWICH 8587526500 9420 ATHENA CIRCLE LA JOLLA CA 920371387 MITCHELL KRONENBERG PHD 40.00 X X 397469 0 47911 SAMUEL STROBER MD 2.00 X 6000 0 0 MARK FISCHER 2.00 X 0 0 0 RICHARD KORNFELD 2.00 X 0 0 0 MICHAEL MARTIN 2.00 X 0 0 0 TOSHIFUMI MIKAYAMA PHD 2.00 X 0 0 0 DAVID DOMINGUEZ 2.00 X 0 0 0 ROBERT DYNES PHD 2.00 X 0 0 0 LEROY HOOD MD PHD 2.00 X 0 0 0 JOHN MAJOR 2.00 X 0 0 0 RHONDA RHYNE 2.00 X 0 0 0 WILLIAM ROHN 2.00 X 0 0 0 DAVID WEBB PHD 2.00 X 0 0 0 CHARLES CARPOWICH 40.00 X 308605 0 55276 AMNON ALTMAN 40.00 X 295016 0 50449 STEPHEN WILSON 40.00 X 198422 0 50267 MARYANN STEWART 40.00 X 162676 0 29147 ANJANA RAO 40.00 X 276841 0 28604 ALESSANDRO SETTE 40.00 X 300166 0 47839 STEPHEN SCHOENBERGER 40.00 X 244331 0 49454 KLAUS LEY 40.00 X 289057 0 50430 JOEL LINDEN 40.00 X 270283 0 44729 2748866 0 454106 38 0 1 0 PILLSBURY WINTHROP SHAW PITTMAN LLP POBOX 60000 SAN FRANCISCO CA 941602391 PATENT SERVICES 391744 SOL PACIFIC LLC 6336 GREENWICH DR SUITE B SAN DIEGO CA 92122 JANITORIAL SERVICES 135253 2COR PARTNERS INC PO BOX 675768 RANCHO SANTA FE CA 92067 DEVELOPMENT CONSULTING SERVICES 104416 3 122506 44500 33901084 9309888 43377978 CONSORTIUM REVENUE 900099 3608126 3608126 3608126 103116 103116 1102392 1102392 0 44500 41390 -41390 -41390 TECHNICAL SERVICES 541900 124424 124424 OTHER INCOME 900099 120219 120219 BUILDING MANAGEMENT 561700 40103 40103 284746 48434968 3608126 164527 1284337 1601236 1384151 188312 28773 228854 228854 17575910 14952781 2549777 73352 1690573 1497683 182865 10025 2496930 2048251 443679 5000 1279336 1141382 127934 10020 180197 78318 101879 182715 182715 3720 3720 228299 80059 148240 350204 62532 217226 70446 197365 159160 37153 1052 527202 285914 239168 2120 4845281 4422276 403127 19878 316430 286045 26930 3455 87602 73362 12027 2213 1705284 1563404 141880 158022 143041 14981 LAB SUPPLIES 7858461 7845456 13005 0 CONSORTIUM 3543270 3543270 0 0 MINOR EQUIPMENT 382140 350382 31758 0 PAGECOSTS/MANUSCRIPT HA 65124 65124 810084 564232 229609 16243 46314239 40775677 5295985 242577 2568 2568 14381604 10789915 7231938 6254903 343749 293750 149404 120647 1051097 401515 18924492 9524814 7761744 9399678 30922104 27262976 8298700 8329223 6547008 736628 0 14845708 9065851 X 15614175 17945093 462221 252032 0 16076396 18197125 30922104 27262976 2120729 0 X 0 1 1 X 1 1 X UCSD MEDICAL CENTER SAN DIEGO CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 1 3720 3720 0 EXPLANATION OF LOBBYING ACTIVITIES: PART II-B, LINE 1: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY IS A MEMBER OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES AND RESEARCH! AMERICA. THESE ORGANIZATIONS DESIGNATE A PORTION OF THE THE DUES THEY RECEIVE FOR LOBBYING ACTIVITIES. 5844347 1362337 4482010 12346408 7592549 4753859 733737 569928 163809 9399678 48434968 46314239 2120729 2120729 48270440 0 48270440 164528 164528 48434968 46149711 0 46149711 164528 164528 46314239 PART XII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDITED FINANCIAL STATEMENTS 164,528. PART XIII, LINE 4B - OTHER ADJUSTMENTS: EXPENSES NETTED AGAINST REVENUE ON AUDITED FINANCIAL STATEMENTS 164,528. EUROPE (INCLUDING ICELAND & GREENLAND) SUBCONTRACTS 60076 MIDDLE EAST AND NORTH AFRICA SUBCONTRACTS 100294 SOUTH AMERICA SUBCONTRACTS 46243 0 0 0 0 0 0 206613 0 206613 0 0 0 0 0 0 AUTUMN SUNSET EVENT 44500 44500 3044 38346 44500 44500 3044 38346 41390 -41390 X X X X X 0 0 0 0 0 0 0 0 0 MITCHELL KRONENBERG PHD 376881 0 0 0 20588 0 36750 0 11161 0 445380 0 0 0 CHARLES CARPOWICH 275247 0 3618 0 29740 0 36750 0 18526 0 363881 0 0 0 AMNON ALTMAN 252567 0 0 0 42449 0 36750 0 13699 0 345465 0 0 0 STEPHEN WILSON 197974 0 0 0 448 0 31750 0 18517 0 248689 0 0 0 MARYANN STEWART 144234 0 0 0 18442 0 22005 0 7142 0 191823 0 0 0 ANJANA RAO 252261 0 0 0 24580 0 20625 0 7979 0 305445 0 0 0 ALESSANDRO SETTE 264398 0 0 0 35768 0 36750 0 11089 0 348005 0 0 0 STEPHEN SCHOENBERGER 209004 0 34281 0 1046 0 32175 0 17279 0 293785 0 0 0 KLAUS LEY 262705 0 25000 0 1352 0 36750 0 13680 0 339487 0 0 0 JOEL LINDEN 250020 0 0 0 20263 0 36750 0 7979 0 315012 0 0 0 SEE PART V X 250000 141667 0 1 1 SEE PART V X 250000 152083 0 1 1 293750 SEE PART V 0 SCHEDULE L, PART II, LOANS TO AND FROM INTERESTED PERSONS: (A) NAME OF PERSON: STEPHEN SCHOENBERGER(B) PURPOSE OF LOAN: HOUSING LOAN(C) ORIGINAL PRINCIPAL AMOUNT: $250,000(D) BALANCE DUE: $141,667(A) NAME OF PERSON: KLAUS LEY(B) PURPOSE OF LOAN: HOUSING LOAN(C) ORIGINAL PRINCIPAL AMOUNT: $250,000(D) BALANCE DUE: $152,083 SCH L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: HILDE CHEROUTRE(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: SPOUSE OF PRESIDENT AND CSO(C) AMOUNT OF TRANSACTION $228,854(D) DESCRIPTION OF TRANSACTION: FULL TIME EMPLOYEE(E) SHARING OF ORGANIZATION REVENUES? = NO(A) NAME OF PERSON: KYOWA HAKKO KIRIN CALIFORNIA INC. ("KKC")(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: AN OFFICER OF KKC IS A DIRECTOR OF THE INSTITUTE(C) AMOUNT OF TRANSACTION $6,113,364(D) DESCRIPTION OF TRANSACTION: RESEARCH FUNDING, FACILITY RENT, COST REIMBURSEMENTS(E) SHARING OF ORGANIZATION REVENUES? = NO FORM 990, PART VI, SECTION B, LINE 11 IN ACCORDANCE WITH WRITTEN INSTITUTE POLICY, A DRAFT OF FORM 990 IS PROVIDED TO ALL BOARD MEMBERS FOR THEIR REVIEW AND COMMENT APPROXIMATELY 30 DAYS PRIOR TO FILING. THIS PROVIDES AN OPPORTUNITY FOR MEMBERS OF THE BOARD TO ASK QUESTIONS AND OBTAIN ADDITIONAL INFORMATION. COMMENTS AND SUGGESTED CHANGES TO THE DRAFT ARE INCORPORATED INTO THE FINAL VERSION OF FORM 990. FORM 990, PART VI, SECTION B, LINE 12C THE INSTITUTE ADMINISTERS THREE SEPARATE CONFLICT OF INTEREST POLICIES APPLYING TO 1) THE BOARD OF DIRECTORS, 2) FACULTY AND SENIOR ADMINISTRATION, AND 3) AN INVESTIGATOR FINANCIAL CONFLICT OF INTEREST POLICY REQUIRED UNDER NATIONAL INSTITUTES OF HEALTH REGULATIONS. THE INSTITUTE REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THESE POLICIES IN ACCORDANCE WITH WRITTEN PROCEDURES, WHICH INCLUDE THE COMPLETION OF DISCLOSURE FORMS BY COVERED INDIVIDUALS, EVALUATION OF COMPLETED FORMS BY A DESIGNATED CONFLICT REVIEW OFFICER, AND AS NECESSARY, FURTHER EVALUATION AND DETERMINATION BY A DESIGNATED CONFLICT REVIEW COMMITTEE. IF A CONFLICT IS DETERMINED, A MANAGEMENT PLAN IS DESIGNED AND MONITORED FOR THE SPECIFIC SITUATION. SUCH PLAN MAY REQUIRE THE COVERED INDIVIDUAL TO ELIMINATE THE CONFLICT. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION DECISIONS FOR THE INSTITUTE'S CEO AND OTHER KEY EMPLOYEES ARE MADE ANNUALLY. ADJUSTMENTS, IF ANY, TYPICALLY TAKE EFFECT ON A JANUARY 1ST CYCLE. FOR THESE PURPOSES, THE INSTITUTE'S HUMAN RESOURCES DEPARTMENT OBTAINS RELEVANT MARKET COMPARABILITY DATA FOR EACH POSITION ON AN ANNUAL BASIS. THE INSTITUTE ALSO PERIODICALLY ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO PERFORM COMPENSATION STUDIES FOR KEY INDIVIDUALS AND TO EVALUATE THE INSTITUTE'S EXECUTIVE COMPENSATION AND BENEFITS PROGRAMS FOR REASONABLENESS. IN ACCORDANCE WITH ITS CHARTER, THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS AND DISCUSSES THIS INFORMATION, AND THE PERFORMANCE OF THE INSTITUTE'S CEO AND KEY EMPLOYEES, AND FORMULATES RECOMMENDED COMPENSATION ACTIONS TO THE FULL BOARD OF DIRECTORS. THE BOARD OF DIRECTORS REVIEWS THESE RECOMMENDATIONS AND RELATED INFORMATION IN DECIDING COMPENSATION LEVELS FOR EACH POSITION. FORM 990, PART VI, SECTION C, LINE 19 THE INSTITUTE MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. SUMMARIZED FINANCIAL DATA IS ALSO MADE AVAILABLE AS PART OF THE INSTITUTE'S ANNUAL REPORT, WHICH IS WIDELY DISTRIBUTED, AND CAN BE DOWNLOADED FROM THE INSTITUTE'S WEB SITE. ALLIMUNE LLC 9420 ATHENA CIRCLE LA JOLLA CA 92037 330841007 RESEARCH CA 0 0 N/A PART I: ALLIMUNE, LLC WAS LEGALLY DISSOLVED AND LIQUIDATED AS OF FEBRUARY 28, 2011.